Trial Profile
An Open-Label Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of DCB-BO1301 as Add-on Therapy to Dacarbazine in Subjects With Advanced Melanoma
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Feb 2021
Price :
$35
*
At a glance
- Drugs DCB BO 1301 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Chung Mei Biopharma
- 18 Feb 2021 Planned initiation date changed from 1 Sep 2020 to 1 Mar 2023.
- 30 Jul 2019 Planned End Date changed from 30 Mar 2019 to 1 Dec 2025.
- 30 Jul 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Sep 2025.